All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Journal of Blood Disorders and Treatment

Sign up for email alert when new content gets added: Sign up

CD19-redirected chimeric antigen receptor (CD19 CAR) T cell in the clinical treatment of human non-Hodgkin’s lymphoma and acute lymphoblastic leukemia

Author(s): Ali R Jazirehi*, Jeffrey D Knott and Emily Chiuzzi

Response rates for patients with B-cell neoplasms such as Non-Hodgkin’s Lymphoma (NHL) and Acute Lymphoblastic Leukemia (ALL) treated with traditional modalities, including chemotherapy, radiation, and bone marrow transplant, are relatively high. However, patients with inherent- or acquiredresistance to first-line treatment options exhibit poor prognosis signifying the need for development of an optimal treatment approach for relapsed/ refractory malignancies of B cell origin. Recently, a new form of immunotherapy using genetically engineered chimeric antigen receptor (CAR) T-cells has been developed. CAR T cells trigger apoptosis in tumor targets in an MHCindependent manner upon recognition and ligation to a specific tumor associated antigen (TAA). Typically, engineered CAR T-cells recognize CD19 specifically, a universal B-cell surface marker expressed in many forms of B-cell malignancies. CD19 CAR T cell-redirected immunotherapy is an attractive option for patients with various CD19+ leukemias (e.g., ALL) and relapsed/refractory NHL. In fact, anti-CD19 CAR T-cell therapy has shown remarkable clinical efficacy in the treatment of these patients. Its significant efficacy coupled with limited toxicities makes CD19 CAR T-cell immunotherapy an ideal treatment approach for ALL and NHL. This review summarizes recent developments in the field of CAR T cell therapy with an emphasis on the utilization of various CD19 CAR T cell constructs in the clinical treatment of NHL and ALL.

Full-Text | PDF

+12 184512974

Recommended Conferences